cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Stockal+Disclaimer.pdf
13 own
16 watching
Current Price
$3.02
$-1.16
(-27.75%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
33.97M
52-Week High
52-Week High
12.00000
52-Week Low
52-Week Low
2.21000
Average Volume
Average Volume
0.76M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization33.97M
icon52-Week High12.00000
icon52-Week Low2.21000
iconAverage Volume0.76M
iconDividend Yield--
iconP/E Ratio--
What does the Stockal+Disclaimer.pdf do?
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Globe Newswire
9 months ago
NEW YORK, June 29, 2023 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased NRx Pharmaceuticals Inc. (f/k/a Big Rock Partners Acquisition Corp.) ("NRXP" or the "Company") (NASDAQ:NRXP) stockprior toMay 24, 2021and still hold...
PR Newswire
10 months ago
NRXP ALERT: Levi & Korsinsky, LLP Announces an Investigation into the Fairness of NRx Pharmaceuticals Inc.'s De-SPAC Merger NRXP ALERT: Levi & Korsinsky, LLP Announces an Investigation into the Fairness of NRx Pharmaceuticals Inc.'s De-SPAC Merger PR Newswire NEW YORK, June 15, 2023...
PR Newswire
10 months ago
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of NRx Pharmaceuticals, Inc. and Encourages Long-Term NRXP / BRPA Shareholders to Contact the Firm SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of NRx Pharmaceuticals, Inc. and Encourages Long-Term NRXP / BRPA Shareholders to...
PR Newswire
10 months ago
NRx Pharmaceuticals Announces Closing of $6.28 Million Registered Direct Offering NRx Pharmaceuticals Announces Closing of $6.28 Million Registered Direct Offering PR Newswire RADNOR, Pa., June 9, 2023 RADNOR, Pa., June 9, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ('NRx...
PR Newswire
1 year ago
NRx Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023 NRx Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023 PR Newswire RADNOR, Pa., March 17, 2023 RADNOR, Pa., March 17, 2023 /PRNewswire/ -- NRx...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$3.02
$-1.16
(-27.75%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00